New directions can take many forms when it comes to oncology these days

It’s been an interesting exercise of late to watch how companies in the oncology arena have been planning and tackling both their new strategic five year reviews, as well as upcoming patent expiries.

If they want to maintain or even improve on their current growth rate then they have to set out a realistic plan for the future.

Some have come across as panicked and unconvincing with that ‘deer in the headlights’ look, while other come across as calm and

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by